miR-212 Increases Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Sensitivity in Non-Small Cell Lung Cancer by Targeting the Antiapoptotic Protein PED

Fondazione IRCCS SDN, Naples, Italy.
Cancer Research (Impact Factor: 9.33). 04/2010; 70(9):3638-46. DOI: 10.1158/0008-5472.CAN-09-3341
Source: PubMed


PED/PEA-15 (PED) is a death effector domain family member of 15 kDa with a broad antiapoptotic function found overexpressed in a number of different human tumors, including lung cancer. To date, the mechanisms that regulate PED expression are unknown. Therefore, we address this point by the identification of microRNAs that in non-small cell lung cancer (NSCLC) modulate PED levels. In this work, we identify miR-212 as a negative regulator of PED expression. We also show that ectopic expression of this miR increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death in NSCLC cells. In contrast, inhibition of endogenous miR-212 by use of antago-miR results in increase of PED protein expression and resistance to TRAIL treatment. Besides, in NSCLC, we show both in vitro and in vivo that PED and miR-212 expressions are inversely correlated, that is, PED is upregulated and miR-212 is rarely expressed. In conclusion, these findings suggest that miR-212 should be considered as a tumor suppressor because it negatively regulates the antiapoptotic protein PED and regulates TRAIL sensitivity.

10 Reads
  • Source
    • "Furthermore, it was observed that low miR-451 expression levels were also associated with shorter overall survival of NSCLC patients, and miRNA-451 could function as a tumor inhibitor in human NSCLC by targeting ras-related protein 14 (RAB14).27 Further, miRNAs such as miR-98, miR-101, miR-93, miR-182, miR-197, miR-212, and miR-451 have tumor-suppressive functions in lung cancer.28–32 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer is the major cause of cancer deaths worldwide due to its late diagnosis and poor outcome. Understanding genomic medicine may widen our vision into the oncogenesis of lung cancer and may open the door to improvements in the clinical management of lung cancer. It is well known that almost half of all genes are regulated by microRNAs (miRNAs). This review focuses on the role of miRNAs in lung cancer and also touches on the value of miRNA-based novel therapies for lung cancers. © 2014 Gao et al. This work is published by Dove Medical Press Limited.
    OncoTargets and Therapy 06/2014; 7:901-906. DOI:10.2147/OTT.S62227 · 2.31 Impact Factor
  • Source
    • "MiR-193a, regulating k-ras and survival, was increased by 776% (p = 0.009) [42]. MiR-212, regulating apoptosis, was increased by 148% (p = 0.009) [43]. Thesetwo cellular processes are known to be aberrant in SLE monocytes [44], [45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gene expression studies of peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE) have demonstrated a type I interferon signature and increased expression of inflammatory cytokine genes. Studies of patients with Aicardi Goutières syndrome, commonly cited as a single gene model for SLE, have suggested that accumulation of non-coding RNAs may drive some of the pathologic gene expression, however, no RNA sequencing studies of SLE patients have been performed. This study was designed to define altered expression of coding and non-coding RNAs and to detect globally altered RNA processing in SLE. Purified monocytes from eight healthy age/gender matched controls and nine SLE patients (with low-moderate disease activity and lack of biologic drug use or immune suppressive treatment) were studied using RNA-seq. Quantitative RT-PCR was used to validate findings. Serum levels of endotoxin were measured by ELISA. We found that SLE patients had diminished expression of most endogenous retroviruses and small nucleolar RNAs, but exhibited increased expression of pri-miRNAs. Splicing patterns and polyadenylation were significantly altered. In addition, SLE monocytes expressed novel transcripts, an effect that was replicated by LPS treatment of control monocytes. We further identified increased circulating endotoxin in SLE patients. Monocytes from SLE patients exhibit globally dysregulated gene expression. The transcriptome is not simply altered by the transcriptional activation of a set of genes, but is qualitatively different in SLE. The identification of novel loci, inducible by LPS, suggests that chronic microbial translocation could contribute to the immunologic dysregulation in SLE, a new potential disease mechanism.
    PLoS ONE 05/2014; 9(5):e93846. DOI:10.1371/journal.pone.0093846 · 3.23 Impact Factor
  • Source
    • "However, DR5-mediated DISC was modified by several anti-apoptotic proteins including PEA-15 resulting in TRAIL resistance in glioblastoma (Bellail et al., 2010). Recently, microRNA-212 has been suggested to be a negative regulator of PEA-15 in NSCLC as overexpression of the microRNA resulting in a reduction in PEA-15 protein levels and increased TRAIL-mediated apoptosis, suggesting they are inversely correlated (Incoronato et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Phosphoprotein enriched in astrocytes-15 (PEA-15) is a cytoplasmic protein that sits at an important junction in intracellular signalling and can regulate diverse cellular processes, such as proliferation and apoptosis, dependent upon stimulation. Regulation of these processes occurs by virtue of the unique interaction of PEA-15 with other signalling proteins. PEA-15 acts as a cytoplasmic tether for the mitogen-activated protein kinases, extracellular signal-regulated kinase 1/2 (ERK1/2) preventing nuclear localisation. In order to release ERK1/2, PEA-15 requires to be phosphorylated via several potential pathways. PEA-15 (and its phosphorylation state) therefore regulates many ERK1/2-dependent processes, including proliferation, via regulating ERK1/2 nuclear translocation. In addition, PEA-15 contains a death effector domain (DED) which allows interaction with other DED-containing proteins. PEA-15 can bind the DED-containing apoptotic adaptor molecule, Fas-associated death domain protein (FADD) which is also dependent on the phosphorylation status of PEA-15. PEA-15 binding of FADD can inhibit apoptosis as bound FADD cannot participate in the assembly of apoptotic signalling complexes. Through these protein-protein interactions, PEA-15-regulated cellular effects have now been investigated in a number of disease-related studies. Changes in PEA-15 expression and regulation have been observed in diabetes mellitus, cancer, neurological disorders and the cardiovascular system. These changes have been suggested to contribute to the pathology related to each of these disease states. As such, new therapeutic targets based around PEA-15 and its associated interactions are now being uncovered and could provide novel avenues for treatment strategies in multiple diseases.
    Pharmacology [?] Therapeutics 03/2014; 143(3). DOI:10.1016/j.pharmthera.2014.03.006 · 9.72 Impact Factor
Show more